Epigenetic modifications of histones in cancer.

Zhao Z, Shilatifard A. · 2019

Read Epigenetic modifications of histones in cancer. by Zhao Z, Shilatifard A. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6868810.txt.

Introduction

Zhao and Shilatifard review histone marks in cancer, in Genome Biology. DNA in a cell is wound around spools of protein called histones; 147 base pairs wrap each spool. Chemical marks on the histones help decide which genes are read. Those marks are versatile and tightly tied to development. When the marking goes wrong, cancer can follow.

The review catalogues the main kinds of histone modification and the enzymes that add or remove them. Many of those enzymes are altered in tumours. Small-molecule inhibitors against them now exist as research tools, and some are in clinical study. The authors explain how the tools reveal what each mark does.

Catalog record

CREATORZhao Z, Shilatifard A.
YEAR2019
COLLECTIONPAPERS
FORMATTXT
FILE SIZE91 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC6868810

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Epigenetic modifications of histones in cancer By Zibo Zhao, Ali Shilatifard Published in: Genome Biology DOI: 10.1186/s13059-019-1870-5 ABSTRACT The epigenetic modifications of histones are versatile marks that are intimately connected to development and disease pathogenesis including human cancers. In this review, we will discuss the many different types of histone modifications and the biological processes with which they are involved. Specifically, we review the enzymatic machineries and modifications that are involved in cancer development and progression, and how to apply currently available small molecule inhibitors for histone modifiers as tool compounds to study the functional significance of histone modifications and their clinical implications. INTRODUCTION In eukaryotic cells, DNA is packed as chromatin whose functional units are nucleosomes. Each nucleosome is composed of an octamer of four core histones (H3, H4, H2A, and H2B), around which is wrapped 147 base pairs of DNA [1]. The globular regions of the histones form the core of the nucleosome, while the N-terminal tails protrude from the nucleosomes and are enriched with a variety of posttranslational modifications (PTMs). PTMs can also occur on the lateral surface of the nucleosome core regions of histones that are in contact with the DNA [2], with both tail and core modifications influencing the chromatin structure by altering the net charge of histones, by altering inter-nucleosomal interactions, and by facilitating the recruitment of specific proteins such as bromo-, chromo-, Tudor, PWWP, MBT, and PHD domain-containing proteins [1]. Histone modifications, and the enzymes implementing them, can contribute to chromatin compaction, nucleosome dynamics, and transcription. These modifications can be implemented in response to intrinsic and external stimuli. Dysregulation of these processes can shift the balance of gene expression and are therefore frequently observed in human cancers, either by gain or loss of function, overexpression, suppression by promoter hypermethylation, chromosomal translocation, or mutations of the histone-modifying enzymes/complexes or even the modification site of the histone [2–4]. Indeed, mutations in chromatin-bound proteins are among the top frequently mutated targets in cancer [5]. The dysregulation of certain chromatin-associated proteins may act as drivers in certain types of cancer [6, 7]. Consequently, abnormal cellular proliferation, invasion, and metastasis and chemoresistance may occur during disease progression [8]. However, there is still a substantial base of knowledge that needs to be gained in order to define the roles of histone modifications and its enzymatic machinery during development and disease settings. This review focuses on the recent progress in our understanding of histone modifications in mammals, highlighting the mechanisms of PTMs in cancer with the availability of new assays, techniques and inhibitors for fine mapping the modifications genome-wide and the potential to use in the treatment of cancers. We will define what marks are epigenetic, and why and how the balance is maintained between different modifications for proper regulation of gene expression. We will also address the histone modifications in cancer as biomarkers of cancer progression and/or prognosis. Histone modifications, modifiers, and their functions in development and cancers Transcription activation and repression are controlled by an array of histone modifiers and chromatin-bound proteins. A balance between specific modifications and modifiers are maintained at the steady state of the cell to maintain the chromatin structure, execute the proper gene expression program, and control the biological outcome (Fig. 1). Once the balance is disrupted, cell phenotypes may be altered and primed for disease onset and progression [9–11]. Therefore, understanding the functions of the key regulators of histone modifications will help us to develop chemical probes to maintain the homeostasis and restore the balanced state of the cell (Fig. 2). Fig. 1Balanced states of transcription maintained by the versatile chromatin proteins and histone modifications. The balanced states of transcription are maintained by the chromatin modifiers and histone modifications. The histone-modifying enzymes are depicted as apples (activation) and oranges (repression) in the two weighing pans respectively. The chromatin states are maintained and balanced by a number of activation marks and repression marks. Histone marks highlighted in bold are considered to be hallmarks of euchromatin (H4K16ac) and heterochromatin (H3K9me3 and H3K27me3) respectively Fig. 2Pharmacological restoration of the epigenetic balance of gene expression in human cancers. a MLL translocation and SEC promote the leukemogenesis in MLL-rearranged leukemia. Enhancing the wild-type MLL1 recruitment to chromatin by hijacking the IL1/IRAK4 and CKII/tasapse1 pathways displaces the MLL chimera and SEC and inhibits leukemogenesis. b MLL3 mutation in the PHD leads to the loss of function of MLL3/COMPASS and decreased enhancer H3K4 methylation. EZH2 inhibition by small molecules (e.g., GSK-126) inhibits EZH2 enzymatic activity and decreases H3K27 methylation to restore the tumor suppressor gene expression. c H3K27M mutation leads to the global increase of H3K27 acetylation and aberrant gene expression. Inhibition of BRD4 by small molecules (e.g., JQ-1) displaces the protein from chromatin and restores the normal-like gene expression and inhibits DIPG from progression We primarily focus this review on methylation, acetylation, and ubiquitination of the PTMs associated with the development and cancers. The other types of modifications including those that are newly identified will also be briefly discussed towards the end of the review. The major types of modifications of histones on tails or within the nucleosome core that are discussed in this review are summarized in Table 1. Table 1Chromatin modifiers, binding factors and functions of selected PTMs on histonesHistonesModificationModifiersBinding factorsFunctionsReferenceH2AK119Ub1RING1A/BBAP1, USP16, USP21, 2A-DUB, USP3, USP22Transcriptional repression[12, 13]H2AXS139p (γH2AX)ATM, ATR, DNA-PKPP2A, Wip1, PP6 and PP4MDC1, CRB2DNA repair[14]H2BK120Ub1RNF20, RNF40USP3, USP7, USP22Transcriptional activation, DNA damage response[15]H3K4me1/2/3SET1A/B, MLL1-4KDM1A/B, KDM2A/B, KDM5A/B/C/DBRWD2/PHIP, MLL,TAF3, CHD1,RAG2, BPTF, PHF2/6/8, JMJD2Transcriptional activation[16–18]K9me1/2/3Suv39H1/2, G9a, GLP, SETDB1KDM1A, KDM3A/B, JMJD1C, KMD4A/B/C/DHP1, ATRXTranscriptional activation (K9me1), repression (K9me2/3), X-inactivation and imprinting (K9me2)[19]S10pAurora B, MSK/RSK/Jil-1PP2A, PP114–3-3ζMitosis, meiosis, transcriptional activation[20]R26me2CARM1PADI4Transcriptional activation[21]K27 acCBP/p300HDACsBRDsTranscriptional activation[22]K27me1/2/3EZH1/2KDM6A/B, KDM7A, PHF8EED, PC, CBX7Transcriptional activation (K27me1); Transcriptional silencing, X-inactivation, bivalent genes/gene poising (K27me2/3)[23]K36me1/2/3NSD1–3, SETD2/3, ASH1L, SETMAR, SMYD2KDM2A/B, KDM4A/B/C/D, JHDM1AZYMND11, PHF19, LEDGFTranscriptional elongation, repression, DNA repair[19]K79me1/2/3DOT1L?p53BP1Transcriptional activation[24]H4K20me1PR-Set7LSD1nCRB2, p53BP1Transcriptional activation[25, 26]K20me2/3SUV4-20H1/2LSD1n, DPY-21CRB2, p53BP1, JMJD2Transcriptional silencing, Heterochromatin[25, 27]K16 acMOFHDACs, Sirt2BRDsTranscriptional activation, DNA repair[28, 29] Methylation Histone methylation is a dynamic process with key roles in development and differentiation [30, 31]. For instance, H3K4 methyltransferases play crucial roles on Hox gene regulation during developmental stage [32, 33]. Aberrant levels of histone methylation are likely to play a causal role in tumorigenesis. The outcomes of methylation on histones are highly context dependent and can be associated with different gene expression status. Histone methylation is intimately associated with transcriptional regulation by influencing chromatin architecture, recruiting transcriptional factors, interacting with initiation and elongation factors, and affecting RNA processing [34]. Histone methylation takes place on the side-chain nitrogen atoms of both lysine and arginine residues, most heavily on histone H3 followed by H4 [35]. Multiple methylation states exist for both lysine and arginine methylation, and these can elicit different outcomes for transcriptional regulation. Lysine can be mono-, di-, or trimethylated by six major classes of histone lysine methyltransferase complexes (KMT1-6) [36]. The KMT1 family contains at least four members in mammals including SUV39H1/2, G9a, GLP, and SETDB1, with H3K9 as the substrate for methylation [37, 38]. The KMT2 family enzymes are found within the macromolecular complex called complex of proteins associated with Set1 (COMPASS) and deposit mono-, di-, or trimethyl marks on H3K4 [16–18]. The KMT3 family contains NSD1, NSD2 (WHSC1), and NSD3 (WHSC1L1) and primarily methylates H3K36 [39]. The KMT4 family has DOT1L as the sole member,

Read the complete text